FDA Drug Approvals — April 2026
47
April 2026
Regulatory
CatchAll identified 47 verified FDA drug approvals and regulatory decisions in April 2026, reviewed across 44,000+ web pages including approval letters, press releases, and regulatory filings.
FDA drug approvals regulatory decisions April 2026
Dataset generated by CatchAll on May 1, 2026. Query reviewed 44,000+ web pages. Events validated against FDA press releases and primary pharmaceutical sources. Clustered using Leiden algorithm to deduplicate coverage across multiple news sources.
44000
<table class="catchall-table"><thead><tr><th>Drug / Decision</th><th>Description</th><th>Date</th><th>Therapeutic Area</th><th>Source</th></tr></thead><tbody><tr><td>Leqembi (lecanemab) label update</td><td>FDA approves expanded label for early Alzheimer treatment</td><td>Apr 2, 2026</td><td>Neurology</td><td>fda.gov</td></tr><tr><td>Keytruda new indication</td><td>Pembrolizumab approved for resectable NSCLC adjuvant therapy</td><td>Apr 5, 2026</td><td>Oncology</td><td>merck.com</td></tr><tr><td>Zepbound obesity expanded approval</td><td>Tirzepatide approved for obesity-related cardiovascular risk reduction</td><td>Apr 9, 2026</td><td>Metabolic / Cardiovascular</td><td>lilly.com</td></tr><tr><td>Dupixent asthma paediatric</td><td>Dupilumab approved for children aged 1-11 with moderate-to-severe asthma</td><td>Apr 12, 2026</td><td>Immunology</td><td>sanofi.com</td></tr><tr><td>CAR-T cell therapy approval</td><td>Breakthrough therapy for relapsed/refractory multiple myeloma</td><td>Apr 16, 2026</td><td>Haematology</td><td>fda.gov</td></tr><tr class="catchall-blurred"><td>████████████</td><td>████████████████████</td><td>Apr 18, 2026</td><td>████████</td><td>████████</td></tr><tr class="catchall-blurred"><td>████████████</td><td>████████████████████</td><td>Apr 20, 2026</td><td>████████</td><td>████████</td></tr><tr class="catchall-blurred"><td>████████████</td><td>████████████████████</td><td>Apr 22, 2026</td><td>████████</td><td>████████</td></tr></tbody></table>